Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases.

Abstract

Given the paradigm of anti-insulin resistance in therapies for metabolic syndrome, there has been considerable interest in adiponectin (APN), an adipocyte-derived sensitizer of insulin receptor signaling. In contrast to hypoadiponectinemia in metabolic syndrome, evidence suggests that Alzheimer's disease (AD) and other diseases, including chronic heart failure (CHF) and chronic kidney disease (CKD), are characterized by hyperadiponectinemia as well as the APN/obesity paradoxes, indicating that a decrease in APN might also be beneficial for these diseases. Thus, distinct from metabolic syndrome, it is anticipated that APN receptor antagonists rather than agonists might be effective in therapy for some chronic diseases.

• Authors: Masaaki Waragai, Gilbert Ho, Yoshiki Takamatsu, Yuka Shimizu, Hiromu Sugino, Shuei Sugama, Takato Takenouchi, Eliezer Masliah, Makoto Hashimoto
• Journal: Drug discovery today (Drug Discov Today) Vol. 23 Issue 6 Pg. 1305-1311 (06 2018) ISSN: 1878-5832 [Electronic] England
• PMID: 29747002 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2018 Elsevier Ltd. All rights reserved.

Chemical References

• ADIPOQ protein, human
• Adiponectin
• Receptors, Adiponectin

Topics

• Adiponectin (deficiency, metabolism)
• Aging (metabolism)
• Animals
• Chronic Disease
• Humans
• Metabolic Syndrome (drug therapy, metabolism)
• Metabolism, Inborn Errors (drug therapy, metabolism)
• Obesity (metabolism)
• Receptors, Adiponectin (agonists, antagonists & inhibitors, metabolism)
• Signal Transduction